Kovitz Investment Group Partners LLC Has $25.87 Million Position in Zoetis Inc. (NYSE:ZTS)

Kovitz Investment Group Partners LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 11.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 158,790 shares of the company's stock after selling 20,037 shares during the period. Kovitz Investment Group Partners LLC's holdings in Zoetis were worth $25,872,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ZTS. Mission Wealth Management LP grew its holdings in Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after acquiring an additional 59 shares during the last quarter. VeraBank N.A. grew its position in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after buying an additional 62 shares during the period. HUB Investment Partners LLC lifted its holdings in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after buying an additional 62 shares during the period. Procyon Advisors LLC boosted its stake in Zoetis by 1.4% in the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after acquiring an additional 63 shares during the last quarter. Finally, Coppell Advisory Solutions LLC raised its position in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after acquiring an additional 64 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock valued at $312,254 over the last three months. Insiders own 0.16% of the company's stock.

Zoetis Stock Up 0.8 %

Shares of Zoetis stock traded up $1.22 on Wednesday, reaching $156.65. 1,613,254 shares of the company were exchanged, compared to its average volume of 2,489,603. The company has a market capitalization of $69.89 billion, a price-to-earnings ratio of 28.64, a PEG ratio of 2.78 and a beta of 0.92. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a 50-day moving average of $158.81 and a 200 day moving average of $167.98.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.28%. Zoetis's dividend payout ratio is 36.56%.

Analyst Ratings Changes

Several research firms have recently issued reports on ZTS. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Piper Sandler boosted their target price on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Finally, Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $214.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.